Longeveron Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Longeveron wird ein Gewinn- und Umsatzwachstum von 47.7% bzw. 65.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 76% pro Jahr wachsen soll.

Wichtige Informationen

47.7%

Wachstumsrate der Gewinne

76.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	27.1%
Wachstumsrate der Einnahmen	65.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	04 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Longeveron rises ~20%, co to present Alzheimer's trial abstract at leading conference

Jul 07

Longeveron: Small-Cap Biotech Targeting Large Alzheimer's Market

May 06

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:LGVN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	5	-24	N/A	N/A	1
12/31/2025	2	-22	N/A	N/A	3
12/31/2024	2	-25	N/A	N/A	3
6/30/2024	1	-28	-17	-16	N/A
3/31/2024	1	-22	-17	-16	N/A
12/31/2023	1	-22	-20	-19	N/A
9/30/2023	1	-21	-18	-17	N/A
6/30/2023	1	-20	-18	-17	N/A
3/31/2023	1	-20	-17	-16	N/A
12/31/2022	1	-19	-15	-14	N/A
9/30/2022	1	-18	-15	-13	N/A
6/30/2022	1	-18	-12	-11	N/A
3/31/2022	1	-17	-12	-11	N/A
12/31/2021	1	-17	-11	-10	N/A
9/30/2021	2	-14	-9	-9	N/A
6/30/2021	4	-10	-7	-7	N/A
3/31/2021	4	-7	-5	-5	N/A
12/31/2020	6	-4	-3	-2	N/A
9/30/2020	6	-3	-2	-2	N/A
12/31/2019	6	-3	-3	-2	N/A
12/31/2018	2	-6	-5	-5	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: LGVN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: LGVN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: LGVN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: LGVNDie Einnahmen des Unternehmens (65.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: LGVNDie Einnahmen des Unternehmens (65.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von LGVN in 3 Jahren voraussichtlich hoch sein wird

Longeveron Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus estimates of losses per share improve by 12%

Price target decreased by 31% to US$8.32

Consensus revenue estimates fall by 14%

Consensus revenue estimates increase by 21%

Price target decreased by 10% to US$11.32

Consensus EPS estimates upgraded to US$3.42 loss

Recent updates

Longeveron Inc. Presents Lomecel-B™? Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Longeveron Inc. Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS)

Consensus estimates of losses per share improve by 12%

Price target decreased by 31% to US$8.32

Consensus revenue estimates fall by 14%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Longeveron Inc. to Report Q2, 2024 Results on Aug 14, 2024

Consensus revenue estimates increase by 21%

Price target decreased by 10% to US$11.32

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)

Consensus EPS estimates upgraded to US$3.42 loss

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $9.000005 million.

Longeveron Inc. has filed a Follow-on Equity Offering.

Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease

Longeveron Inc. Announces U.S. FDA Grants Lomecel-B Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease

Longeveron Inc. Elects Neha Motwani to Its Board of Directors

Longeveron Inc. Appoints Roger Hajjar to Board of Directors

Price target decreased by 12% to US$12.30

Consensus EPS estimates upgraded to US$3.91 loss

Longeveron Inc., Annual General Meeting, Jul 02, 2024

Consensus revenue estimates increase by 931%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Longeveron Inc. Announces Board Changes

Longeveron Inc. to Report Q1, 2024 Results on May 14, 2024

Consensus EPS estimates upgraded to US$5.85 loss

Price target decreased by 48% to US$37.50

New major risk - Share price stability

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $5.248428 million.

New major risk - Shareholder dilution

New major risk - Market cap size

Longeveron Announces 1-For-10 Reverse Stock Split to Regain Compliance

Longeveron Inc. has filed a Follow-on Equity Offering.

Longeveron Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Longeveron Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Full year 2023 earnings: EPS misses analyst expectations

Longeveron Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $2.365 million.

Longeveron Inc. has filed a Follow-on Equity Offering in the amount of $2.195588 million.

Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the Clear Mind Phase 2A Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’S Disease

Long-Term Survival Data from Longeveron’s Elpis 1 Trial Presented At the 2023 Scientific Sessions of the American Heart Association

Longeveron Inc. to Report Q3, 2023 Results on Nov 10, 2023

Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from Clear MIND Phase 2a Clinical Trial of Lomecel-B™? for the Treatment of Mild Alzheimer's

New minor risk - Shareholder dilution

Consensus revenue estimates increase by 41%

Longeveron Inc. Announces Positive Top-Line Results for Lomecel-B in Its Clear Mind Phase 2A Clinical Trial in the Treatment of Mild Alzheimer’s Disease

Director exercised options to buy US$70k worth of stock.

New major risk - Revenue size

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Longeveron Inc Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome

Longeveron Inc. to Report Q2, 2023 Results on Aug 11, 2023

Longeveron Inc. Announces the Appointment of Lisa Locklear as Chief Financial Officer, Effective July 31, 2023

Longeveron Inc. Appoints Nataliya Agafonova M.D. as Chief Medical Officer

High number of new directors

Longeveron Inc. Approves Bord Appointments

Longeveron Inc. Announces Resignation of James Clavijo as CFO

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Longeveron Inc Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome

Longeveron Inc. to Report Q1, 2023 Results on May 12, 2023

Full year 2022 earnings released: US$0.90 loss per share (vs US$0.90 loss in FY 2021)

Price target decreased to US$15.50

Longeveron Provides Corporate Update

Consensus forecasts updated

Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely?

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Longeveron Inc. Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’S Disease

Longeveron Inc. to Report Q3, 2022 Results on Nov 14, 2022

Longeveron Inc.: A New Approach To Treat Alzheimer's